Advertisement

Archives of Gynecology and Obstetrics

, Volume 292, Issue 4, pp 749–756 | Cite as

Safety of insulin analogs during pregnancy: a meta-analysis

  • ShiShi Lv
  • JiYing Wang
  • Yong XuEmail author
Review

Abstract

Objective

The objective of this study was to assess the safety of four insulin analogs (aspart, lispro, glargine, and detemir) for the treatment of diabetes in pregnancy.

Methods

We searched Embase, Pubmed, and the Cochrane Central Register for Controlled Trials database through May 31, 2014. All articles were reviewed by two independent researchers, and if a discrepancy was noted, a third researcher was consulted. Results data were summarized by RevMan 5.2 software.

Results

Our search resulted in the retrieval and screening of 3519 studies. Of those, 24 studies met the eligibility criteria; the studies reported on a total of 3734 women with pre-gestational or gestational diabetes during pregnancy. The use of lispro was associated with lower rates of neonatal jaundice (RR = 0.63) and severe maternal hypoglycemia (RR = 0.33) than regular insulin. Lispro use was also associated with higher birth weight (WMD = 116.44) and an increased incidence of large for gestational age (LGA) births (RR = 1.42) compared with regular insulin. Rates of cesarean section and macrosomia were similar in pregnant women treated with aspart and regular insulin. Birth weights and rates of severe maternal hypoglycemia, respiratory dysfunction syndrome, and neonatal intensive care unit admission were similar after pregnant women were treated with glargine and NPH insulin. Rates of LGA, macrosomia, and neonatal hypoglycemia were similar after pregnant women were treated with detemir and NPH insulin.

Conclusions

Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study. However, lispro was related to higher birth weight and increased rate of LGA in neonates. More high-quality randomized controlled trials are needed to clarify the best treatment options for diabetes during pregnancy.

Keywords

Insulin analogs Pregnancy Meta 

Notes

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled, “Safety of insulin analogs during pregnancy: a meta-analysis.”

References

  1. 1.
    Lawrence JM, Contreras R, Chen W et al (2008) Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 31:899–904CrossRefPubMedGoogle Scholar
  2. 2.
    DeSisto CL, Kim SY, Charma AJ (2014) Prevalence estimates of gestational diabetesmellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Prev Chronic Dis 19(11):E104Google Scholar
  3. 3.
    HAPO Study Cooperative Research Group, Metaqer BE, Lowe LP et al (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002CrossRefGoogle Scholar
  4. 4.
    Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro:a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMedGoogle Scholar
  5. 5.
    Lapolla A, Dalfra MG, Spezia R et al (2008) Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol 45:61–66CrossRefPubMedGoogle Scholar
  6. 6.
    Durnwald CP, Landon MB (2008) A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med 21:309–313CrossRefPubMedGoogle Scholar
  7. 7.
    Banerjee M, Bhattacharya A, Hughes SM et al (2009) Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus. Pract Diabetes Int 26:366–370CrossRefGoogle Scholar
  8. 8.
    Aydin Y, Berker D, Direktor N et al (2008) Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract 80(44):4–448Google Scholar
  9. 9.
    García-Domínguez M, Herranz L, Hillman N et al (2011) Use of insulin lispro during pregnancy in women with pregestational diabetes mellitus. Med Clin 137:581–586CrossRefGoogle Scholar
  10. 10.
    Cypryk K, Sobczak M, Pertyńska-Marczewska M et al (2004) Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 10:PI29–PI32PubMedGoogle Scholar
  11. 11.
    Evers IM, de Valk HW, Mol BW et al (2002) Macrosomia despite good glycaemic control in type1 diabetic pregnancy results of a nationalwide study in the Netherlands. Diabetologia 45:1484–1489CrossRefPubMedGoogle Scholar
  12. 12.
    Colatrella A, Visalli N, Abbruzzese S et al (2013) Comparison of insulin lispro protamine suspension with NPH insulin in pregnant women with type 2 and gestational diabetes mellitus: maternal and perinatal outcomes. Int J Endocrinol 2013:151975PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Balaji V, Balaji MS, Alexander C et al (2012) Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study. Gynecol Endocrinol 28:529–532CrossRefPubMedGoogle Scholar
  14. 14.
    Balaji V, Balaji MS, Alexander C et al (2010) Premixed insulin aspart 30 (Bia sp 30) vs premixed human insulin 30 (Bhi 30) in gestational diabetes mellitus—a pilot study. J Assoc Physician India 58:99–101Google Scholar
  15. 15.
    Hod M, Damm P, Kaaja R et al (2008) Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198:186.e1–186.e7CrossRefGoogle Scholar
  16. 16.
    Poyhonen-Alho M, Ronnemaa T, Saltevo J et al (2007) Use of insulin glargine during pregnancy. Acta Obstetricia et Gynecologica 86:1171–1174CrossRefGoogle Scholar
  17. 17.
    Fang YM, MacKeen D, Egan JF et al (2009) Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 22:249–253CrossRefPubMedGoogle Scholar
  18. 18.
    Egerman RS, Ramsey RD, Kao LW et al (2009) Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol 26:591–595CrossRefPubMedGoogle Scholar
  19. 19.
    Imbergamo MP, Amato MC, Sciortino G et al (2008) use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther 30:1476–1484CrossRefPubMedGoogle Scholar
  20. 20.
    Negrato CA, Rafacho A, Negrato G et al (2010) Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract 89:46–51CrossRefPubMedGoogle Scholar
  21. 21.
    Price N, Bartlett C, Gillmer M (2007) Use of insulin glargine during pregnancy: a case–control pilot study. BJOG 114:453–457CrossRefPubMedGoogle Scholar
  22. 22.
    Smith JG, Manuck TA, White J et al (2009) Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol 26:57–62CrossRefPubMedGoogle Scholar
  23. 23.
    Imbergamo MP, Amato MC, Amodeo R et al (2012) Use of basal insulin analog detemir in pregnant women with type1 diabetes:a case-control retrospective study. Giorn Ital Ostet Ginecol 34:491–498Google Scholar
  24. 24.
    Hod M, Mathiesen ER, Jovanovic L et al (2014) A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 27:7–13PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Edson EJ, Bracco OL, Vambergue A et al (2010) Managing diabetes during pregnancy with insulin lispro :a safe alternative to human insulin. Endocr Pract 16:1020–1027CrossRefPubMedGoogle Scholar
  26. 26.
    Blanco CG, Ballesteros AC, Saladich IG et al (2011) Glycemic control and pregnancy outcomes in women with type 1 Diabetes mellitus using lispro versus regular insulin: a systematic review and meta-analysis. Diabetes Technol Ther 13:907–911CrossRefGoogle Scholar
  27. 27.
    Elhddad AS, Lashen H (2013) Fetal growthin relation tomaternal and fetal IGF-axes: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 92:997–1006CrossRefPubMedGoogle Scholar
  28. 28.
    Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefPubMedGoogle Scholar
  29. 29.
    Wilde MI (1997) Mc Tavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597–614CrossRefPubMedGoogle Scholar
  30. 30.
    Boskovic R, Knie B, Feig DS et al (2003) Transfer of insulin lispro across the human placenta. Diabetes Care 26:1390–1394CrossRefPubMedGoogle Scholar
  31. 31.
    The Guideline Development Group (2008) Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ 336:714–717PubMedCentralCrossRefGoogle Scholar
  32. 32.
    Blumer I, Hadar E, Hadden DR et al (2013) Diabetes and Pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4227–4249CrossRefPubMedGoogle Scholar
  33. 33.
    Pollex E, Moretti ME, Koren G et al (2011) Safety of Insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother 45:9–16CrossRefPubMedGoogle Scholar
  34. 34.
    Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743–1753CrossRefPubMedGoogle Scholar
  35. 35.
    Pollex EK, Feig DS, Lubetsky A et al (2010) Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 33:29–33PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Callesen NF, Damm J, Mathiesen JM et al (2013) Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes:comparison of glycaemic control and pregnancy outcome. J Mater Fetal Neonatal Med 26:588–592CrossRefGoogle Scholar
  37. 37.
    Shankardass K, O’campo P, Dodds L et al (2014) Magnitude of income- related disparities in adverse perinatal outcomes. BMC Pregnancy Childbith 14:96CrossRefGoogle Scholar
  38. 38.
    Blumenshine P, Egerter S, Barclay CJ et al (2010) Socioeconomic disparities in adverse birth outcomes: a systematic review. Am J Prev Med 39:263–272CrossRefPubMedGoogle Scholar
  39. 39.
    Mortense LH (2013) Socioeconomic inequality in birth weight and gestational age in Denmark 1996-2007: using a family-based approach to explore alternative explanations. Soc Sci Med 76:1–7CrossRefGoogle Scholar
  40. 40.
    Scifres CM, Feqhali MN, Althouse AD et al (2014) Effect of excess gestational weight gain on pregnancy outcomes in women with type1 diabetes. Obstet Gynecol 123:1295–1302CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of EndocrinologyAffiliated Hospital of Luzhou Medical CollegeLuzhouChina

Personalised recommendations